More on PHAR
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $9.63 |
|
|||
| Open | $9.50 | ||||
| 52 Wk High | $0.00 | ||||
| 52 Wk Low | $0.00 | ||||
| Day High | $9.52 | ||||
| Day Low | $9.31 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 9,030 | ||||
- Form 6-K Pharming Group N.V. For: Oct 14
- Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026
- Form 6-K Pharming Group N.V. For: Sep 29
- Pharming CEO steps down; interim co-CEOs named
- Pharming announces CEO transition
- Form 6-K Pharming Group N.V. For: Sep 25
- FDA accepts Pharming's sNDA for Joenja in lower-weight children
- Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS
- Canaccord Reiterates Buy Rating on Pharming Group (PHAR)
- Form 6-K Pharming Group N.V. For: Sep 22
Entities mentioned with PHAR
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Earnings | View Related Stories »
- PDUFA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
